Company intelligence / Profile preview

Boryung Biopharma

Seoul, Seoul Special City, South Koreamfds.go.kr ↗

Ownership: Private
Development stage: Commercial

Overview

Boryung Biopharma is a leading South Korean developer and manufacturer of vaccines and specialty biologics. The company has several approved vaccines—including Korea’s first oral typhoid vaccine—and produces eight of the 18 vaccines listed in the National Immunization Program. It also develops specialty drugs, diagnostic kits, cord blood products, genetic tests, and fluids. The company has demonstrated stable growth with increasing sales and operating profit in recent years.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Prophylactic vaccineAllergen extractMultivalent vaccine
Industry: Biotech

Drug pipeline

10 assets

BR-TD-1001

9 more assets in the full pipeline.

Request access →

Partnerships

KL& Partners consortium partnersStallergenes SA

Beyond the preview

Go deeper on Boryung Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boryung Biopharma.

Explore the full profile